Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from LB Pharmaceuticals, Inc. ( (LBRX) ) is now available.
On November 12, 2025, LB Pharmaceuticals announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025. With over 20 years of experience in the biopharmaceutical industry, particularly in neuroscience commercialization, Ms. Pai Panandiker’s leadership is expected to be pivotal as the company advances LB-102 toward registration and commercialization. Her expertise in launching and scaling global brands will be crucial for LB Pharmaceuticals as it prepares to bring its innovative therapy for schizophrenia and bipolar depression to market.
The most recent analyst rating on (LBRX) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on LB Pharmaceuticals, Inc. stock, see the LBRX Stock Forecast page.
More about LB Pharmaceuticals, Inc.
LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is advancing its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
Average Trading Volume: 245,061
For an in-depth examination of LBRX stock, go to TipRanks’ Overview page.